Claims for Patent: 7,897,623

Summary for Patent: 7,897,623

Title:	.omega.-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
Abstract:	This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s):	Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Carlisle, MA), Khire; Uday R. (Orange, CT), Lowinger; Timothy B. (Carlisle, MA), Scott; William J. (Guilford, CT), Smith; Roger A. (Chester Springs, PA), Wood; Jill E. (Ft. Collins, CO), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert N. (North Haven, CT)
Assignee:	Bayer Healthcare LLC (Tarrytown, NY)
Application Number:	11/845,597
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,897,623
Patent Claims:	1. A pharmaceutical composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula X ##STR00186## or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 2. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula X ##STR00187## 3. A pharmaceutical composition comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula X ##STR00188## or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier. 4. The pharmaceutical composition of claim 3 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula X ##STR00189## 5. A tablet comprising N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula X ##STR00190## or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. 6. A tablet of claim 5 wherein the pharmaceutically acceptable salt thereof is a tosylate salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyr- idyloxy)phenyl)urea of the formula X ##STR00191## 7. A tablet of claim 5 wherein the pharmaceutically acceptable excipient is a diluent, a granulating agent, a disintegrating agent or a binding agent. 8. A tablet of claim 6 wherein the pharmaceutically acceptable excipient is a diluent, a granulating agent, a disintegrating agent or a binding agent.